Cost of skeletal complications from bone metastases in six European countries

References

• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94
   PubMed Web of Science ®Google Scholar
• Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16:879-89
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Wilsdon T, Fiz E and Haderi A. A comparative analysis of the role and impact of Health Technology Assessment: 2013. Charles River Associates, 2014. Brussels, Belgium http://www.efpia.eu/uploads/documents/cra-comparative-analysis.pdf. Accessed October 2015
   Google Scholar
• Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992;2:1-4
   PubMedGoogle Scholar
• Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7
   PubMedGoogle Scholar
• Groot MT, Boeken Kruger CG, Pelger RC, et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32
   PubMed Web of Science ®Google Scholar
• Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Decroisette C, Monnet I, Berard H, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol 2011;6:576-82
   PubMed Web of Science ®Google Scholar
• Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-6
   PubMed Web of Science ®Google Scholar
• Hechmati G, Cure S, Gouepo A, et al. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ 2013;16:691-700
   PubMedGoogle Scholar
• Hoefeler H, Duran I, Hechmati G, et al. Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective – prospective observational study – a cohort from 4 European countries. J Bone Oncol 2014;3:40-8
   PubMed Web of Science ®Google Scholar
• Body JJ, Pereira J, Sleeboom H, et al. Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ 2015; DOI: 10.1007/s10198-10015-10716-10197.
   PubMed Web of Science ®Google Scholar
• Giermaziak W. [Impact Reimbursement Act on the pharmaceutical market in Poland]. Pol Merkur Lekarski 2014;36:270-3
   PubMedGoogle Scholar
• Delmore G, Biteeva I, Steinmann K, et al. Direct medical costs associated with skeletal-related events in Switzerland. Presented at the European Conference on Health Economics 2012. Zurich, Switzerland: 2012
   Google Scholar
• Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200
   PubMed Web of Science ®Google Scholar
• European Commission, Eurostat. Consumer prices - inflation and comparative price levels. Eurostat, 2012. Luxembourg http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Consumer_prices_-_inflation_and_comparative_price_levels. Accessed November 2015
   Google Scholar
• Eurostat and OECD. Eurostat-OECD methodological manual on purchasing power parities. Eurostat, 2012. Luxembourg http://www.oecd.org/std/pricesandpurchasingpowerparitiesppp/eurostat-oecdmethodologicalmanualonpurchasingpowerparitiesppps.htm Accessed November 2015
   Google Scholar
• Felix J, Andreozzi V, Soares M, et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health 2011;14:499-505
   PubMed Web of Science ®Google Scholar
• Bahl A, Hoefeler H, Duran I, et al. Health resource utilization associated with skeletal-related events in patients with advanced prostate cancer: a European subgroup analysis from an observational, multinational study. J Clin Med 2014;3:883-96
   PubMedGoogle Scholar
• Lorusso V, Duran I, Garzon-Rodriguez C, et al. Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Alpha subgroup analysis from a prospective multinational study. Mol Clin Oncol 2014;2:701-8
   PubMedGoogle Scholar
• Luftner D, Lorusso V, Duran I, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus 2014;3:328
   PubMed Web of Science ®Google Scholar
• Duran I, Garzon C, Sanchez A, et al. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. Clin Transl Oncol 2014;16:322-9
   PubMed Web of Science ®Google Scholar
• Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) Engl2010;19:755-60
   PubMed Web of Science ®Google Scholar
• OECD, Inflation (CPI) (indicator). OECD, 2015. Paris, France https://data.oecd.org/price/inflation-cpi.htm Accessed October 2015
   Google Scholar